Myeloproliferative neoplasms trials in Italy

In Italy 42 Also abroad 213

42 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in Italy
CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)
Where
Pescara, Torino
Age
18 years and over
People
50
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07645755
No phaseNot yet taking people in Italy
ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
Where
Torino
Age
18 years and over
People
25
Run by
Carmen Fava
See details and how to joinNCT07518940
Phase 3Taking people
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Where
Ancona, Bari, Bergamo, Bologna, Catania, Cuneo, Florence, Meldola, Milan, Novara, Palermo, Reggio Calabria, Reggio Emilia, Rome, Turin, Udine
Age
18 years and over
People
220 worldwide
Run by
Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00
No phaseTaking people
Feasibility of a Multi-omics Platform for Hematological Malignancies
Where
Parma
Age
2 years and over
People
1,040
Run by
Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07445438
No phaseTaking people
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Where
Parma
Age
1 year and over
People
250
Run by
Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07445984
No phaseTaking people
A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept
Where
Parma
Age
18 years and over
People
265
Run by
Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07419178
No phaseTaking people
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Where
Palermo, Perugia
Age
1 year and over
People
300
Run by
Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07403630
Phase 2Taking people
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Where
Bologna, Genova, Meldola, Milan, Novara, Orbassano, Pavia, Rome, Torino
Age
18 years and over
People
58 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT05980806
Phase 2Taking people
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
Where
Bari, Bologna, Brescia, Florence, Genoa, Milan, Reggio Emilia, Rome, Varese, Verona
Age
18 years and over
People
135 worldwide
Run by
Takeda
See details and how to joinNCT05037760 · EU 2023-507468-38-00
Phase 3Taking people
An extension study for patients previously enrolled in studies with pelabresib
Where
Florence, Novara, Varese
Age
18 years and over
People
34 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT06401356 · EU 2023-508950-24-00
No phaseTaking people
Unveiling the Germline Predisposition to Myeloproliferative Neoplasms
Where
Pavia
Age
18 years and over
People
313
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT07204392
Phase 3Taking people
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Where
Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Forlì, Milan, Novara, Orbassano, Palermo, Pavia, Pesaro, Reggio Emilia, Rome, Turin, Varese
Age
18 years and over
People
600 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT06479135
No phaseTaking people
Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells
Where
Pavia
Age
18 years and over
People
10
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT06896344
Phase 2Taking people
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Where
Genoa, Rozzano
Age
18 years to 99 years
People
42
Run by
Istituto Clinico Humanitas
See details and how to joinNCT06892223 · EU 2024-516974-31-00
No phaseTaking people
Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Where
Bologna, Cagliari, Catania, Cosenza, Ferrara, Genoa, Milan, Monza, Naples, Padova, Parma, Pesaro, Piacenza, Ravenna, Reggio Calabria, Rimini, Rome, Siena, Turin, Udine, Verona, Viterbo
Age
18 years and over
People
1,055
Run by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT06516406
No phaseTaking people
Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
Where
Bari, Bologna, Brescia, Catania, Naples, Roma, Torino, Udine, Verona, Viterbo
Age
18 years to 99 years
People
500
Run by
University of Milano Bicocca
See details and how to joinNCT05553873
Phase 1/2Taking people
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Where
Bologna, Milan, Perugia
Age
18 years and over
People
70 worldwide
Run by
Telios Pharma, Inc.
See details and how to joinNCT05280509